KMDA · Kamada Ltd · Earnings Call Transcripts & Audio
Market Cap
$457.07M
Shares
57.71M
Kamada Ltd Earnings Call Transcripts
Quarterly earnings calls for Kamada Ltd (KMDA), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$28.09M
−$1.83M
'22 Q1
22-03-31
▼99.9%
$32,217
$484
'22 Q3
22-09-30
·
$77.62M
$3.43M
'22 Q4
22-12-31
▼99.9%
$30,710
−$1,809
'23 Q1
23-03-31
▲58.7%
$37.44M
$1.81M
'23 Q2
23-06-30
▲117645.3%
$37.93M
$3.22M
'23 Q3
23-09-30
▼13.5%
$67.11M
$3.25M
'23 Q4
23-12-31
▲122778.5%
$37.74M
$2.37M
'24 Q1
24-03-31
▲13.4%
$42.47M
$4.43M
'24 Q2
24-06-30
▲10%
$41.74M
$3.86M
'24 Q3
24-09-30
▲16.6%
$44.02M
$3.96M
'25 Q1
25-03-31
▲12.6%
$47.01M
$5.30M
'25 Q3
25-09-30
LATEST
▲14.5%
$44.68M
$3.56M
'25 Q4
26-03-11
Earnings call
FY26 · Q2
2026-08-12
Kamada Ltd (KMDA) Q2 2026 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Kamada Ltd (KMDA) Q1 2026 Earnings Call Transcript
Confident tone
Business development and M&A
Plasma collection centers
CYTOGAM (anti-CMV) and post-marketing studies
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-11
Kamada Ltd (KMDA) Q4 2025 Earnings Call Transcript
Confident tone
2025 financial results and dividend
CYTOGAM and SHIELD study
Plasma collection centers
Revenue
$44.68M*
▲ 14.5% YoY Gross margin
38.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Kamada Ltd (KMDA) Q3 2025 Earnings Call Transcript
Confident tone
Cytogam CMV immunoglobulin and SHIELD study
GLASSIA / alpha-1 antitrypsin (Glacia) ex-US and royalties
Plasma collection centers (Houston and San Antonio)
Revenue
$47.01M
▲ 12.6% YoY Diluted EPS
$0.09
▲ 28.6% YoY Gross margin
42.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Kamada Ltd (KMDA) Q1 2025 Earnings Call Transcript
Confident tone
CYTOGAM Post-Marketing Research Program
Commercial Portfolio Diversification
Business Development and M&A
Revenue
$44.02M
▲ 16.6% YoY Diluted EPS
$0.07
▲ 75% YoY Gross margin
47.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q3
2024-09-30
Kamada Ltd (KMDA) Q3 2024 Earnings Call Transcript
Confident tone
Revenue and EBITDA Growth
InnovAATe Phase 3 Trial
Plasma Collection Centers Expansion
Revenue
$41.74M
▲ 10% YoY Diluted EPS
$0.07
▲ 16.7% YoY Gross margin
41.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Kamada Ltd (KMDA) Q2 2024 Earnings Call Transcript
Confident tone
Commercial portfolio growth (KEDRAB and CYTOGAM)
Partnerships for inhaled AAT
Financial performance and profitability
Revenue
$42.47M
▲ 13.4% YoY Diluted EPS
$0.08
▲ 100% YoY Gross margin
44.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Kamada Ltd (KMDA) Q1 2024 Earnings Call Transcript
Confident tone
KEDRAB and CYTOGAM growth
Financial performance and guidance raise
Biosimilars portfolio in Israel
Revenue
$37.74M
▲ 122778.5% YoY Diluted EPS
$0.04
Gross margin
44.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Kamada Ltd (KMDA) Q4 2023 Earnings Call Transcript
Revenue
$67.11M*
▼ 13.5% YoY Gross margin
39.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Kamada Ltd (KMDA) Q3 2023 Earnings Call Transcript
Revenue
$37.93M
▲ 117645.3% YoY Diluted EPS
$0.06
▲ 500% YoY Gross margin
39.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Kamada Ltd (KMDA) Q2 2023 Earnings Call Transcript
Revenue
$37.44M
▲ 58.7% YoY Diluted EPS
$0.04
Gross margin
38.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Kamada Ltd (KMDA) Q1 2023 Earnings Call Transcript
Revenue
$30,710
▼ 99.9% YoY Diluted EPS
$-0.04
Gross margin
38.6%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Kamada Ltd (KMDA) Q4 2022 Earnings Call Transcript
Revenue
$77.62M*
Gross margin
36.3%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Kamada Ltd (KMDA) Q3 2022 Earnings Call Transcript
Revenue
$32,217
▼ 99.9% YoY Diluted EPS
$0.01
Gross margin
39.9%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Kamada Ltd (KMDA) Q1 2022 Earnings Call Transcript
Revenue
$28.09M
Diluted EPS
$-0.04
Gross margin
40.2%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Kamada Ltd (KMDA) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Kamada Ltd (KMDA) Q3 2021 Earnings Call Transcript
Revenue
$23.03M
▼ 34.8% YoY Diluted EPS
$-0.02
▼ 113.3% YoY Gross margin
24.9%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Kamada Ltd (KMDA) Q2 2021 Earnings Call Transcript
Revenue
$24.24M
Diluted EPS
$0.02
Gross margin
37.4%
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Kamada Ltd (KMDA) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Kamada Ltd (KMDA) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Kamada Ltd (KMDA) Q3 2020 Earnings Call Transcript
Revenue
$35.33M
Diluted EPS
$0.15
Gross margin
42.0%
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Kamada Ltd (KMDA) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Kamada Ltd (KMDA) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–23 of 23 earnings calls
Key facts
CIK
1567529
CUSIP
M6240T109
13F (30d)
16 filings
16 filers
Visit website
Investor relations